Clinical Trials Logo

Filter by:
NCT ID: NCT05707520 Recruiting - Clinical trials for Liver Transplant Rejection

Long-term Benefit of MPA in Liver Transplantation

Start date: December 4, 2022
Phase:
Study type: Observational

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

NCT ID: NCT05707468 Not yet recruiting - Clinical trials for Oligometastatic Prostate Carcinoma

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial is to compare the safety and feasibility outcomes of metastasis-directed neoadjuvant radiotherapy (naRT) and neoadjuvant androgen deprivation therapy (naADT) followed by robotic-assisted radical prostatectomy (RARP) to ADT combined with abiraterone for treating OMPC.

NCT ID: NCT05707442 Recruiting - Clinical trials for Venous Sinus Stenosis

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

Start date: October 31, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.

NCT ID: NCT05707377 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Start date: April 17, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

NCT ID: NCT05707351 Active, not recruiting - Hemophilia A Clinical Trials

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Start date: March 27, 2023
Phase: Phase 3
Study type: Interventional

The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically. Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.

NCT ID: NCT05707325 Recruiting - Cancer Clinical Trials

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

Reboot-101
Start date: October 31, 2022
Phase: Phase 1
Study type: Interventional

This phase studies the engineered red blood cells with PD-1 inhibitor pembrolizumab(WTX212), the natural biological metabolic function of red blood cells can make the carried pembrolizumab directionally distributed in the spleen tissue and activitate T cells, suggesting that this product may solve the problem that PD-1 treatment failure.

NCT ID: NCT05707299 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Effect of Intradermal Acupuncture on Gallbladder Meridian Points on Cerebral Hemodynamics in Relevant Brain Regions for Major Depressive Disorder Based on fNIRS Technology

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Gallbladder meridian(GB) acupoints may play an important role in the treatment of major depressive disorder (MDD). Therefore, this study is designed to focus on the traditional Chinese medicine (TCM) theory of " gallbladder dominating decision ", take the GB as the entry point, and use functional Near-Infrared Spectroscopy(fNIRS) technology to observe the effect of intradermal acupuncture on the cerebral hemodynamic indexes of the prefrontal cortex and bilateral temporal cortex of patients with MDD.

NCT ID: NCT05706441 Completed - COVID-19 Clinical Trials

Lung and Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in COVID-19 Patients

Start date: January 11, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the function of lung and diaphragm ultrasound during weaning from mechanical ventilation in COVID-19 patients. The aim of this study was that the lung ultrasound score and diaphragm muscle mobility could be a potential predictive factor of weaning success.

NCT ID: NCT05706415 Recruiting - Clinical trials for AI Assist in the Diagnosis of Pancreatic Solid Lesions

AI Assisted the Diagnosis of Pancreatic Solid Lesions

Start date: January 21, 2023
Phase:
Study type: Observational

Solid lesions of the pancreas mainly include tumor and non tumor lesions. More than 90% of pancreatic tumor lesions are pancreatic cancer, which is characterized by high mortality and poor prognosis and requires surgical treatment; Non-tumor lesions of the pancreas are mainly inflammatory lesions, which usually do not require surgical treatment, but can be treated with drugs. The common ones are chronic pancreatitis and autoimmune pancreatitis, with a good prognosis. Clinically, the differential diagnosis between them is very difficult. Multi-disciplinary diagnosis and treatment of MDT makes our understanding of pancreatic diseases increasingly rich and in-depth. From disease diagnosis to preoperative evaluation and curative effect evaluation, non-invasive imaging involves almost every link under MDT mode. In view of this, improving the differential diagnosis of pancreatic solid space-occupying lesions on imaging will be more conducive to the diagnosis and treatment under MDT mode, so new technologies such as artificial intelligence should be considered. Our goal is to develop a clinically applicable artificial intelligence system, which uses multiple modes to simulate the routine clinical workflow and assist in the diagnosis of benign and malignant pancreatic solid space-occupying lesions.

NCT ID: NCT05706207 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.